Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
MPH Health Care AG is a listed investment holding company headquartered in Berlin, Germany, founded in 2008. It focuses on acquiring, developing, and managing stakes in high-growth healthcare segments, including treatments for chronic diseases such as oncology, HIV/AIDS, neurology, and rheumatology, as well as medical aesthetic services and digitalization in healthcare. The company operates through Beauty, Pharma, and Real Estate segments, with key portfolio holdings like HAEMATO AG for pharmaceuticals and generics in cancer and chronic therapies; M1 Kliniken AG, a leader in aesthetic surgery, plastic treatments, and beauty medicine; and MPH Ventures, investing in cytostatic solutions via Pharmigon GmbH and real estate through CR Capital Real Estate AG. MPH Health Care AG also pursues opportunities in other profitable sectors like residential real estate development in metropolitan areas. Employing a lean team of two and approximately 4.28 million shares outstanding, it emphasizes long-term value creation and supports shareholders through an attractive dividend policy, playing a niche role in channeling capital to innovative healthcare and growth-oriented enterprises across Germany.
€23.60
€0.40 (-1.67%)
EOD Aug 14, 2026
The business is unprofitable at the operating level (-800.58% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 41.8% YoY. Margins deteriorated 1339.8pp alongside, both lines moving the wrong way.
Free cash flow declined 93% versus the prior year, cash generation momentum has weakened. ROIC dropped from 11.83% to -8.29%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€4M
▼ -41.8% YoY
Net Income (TTM)
-€29M
▼ -191.5% YoY
Op. Margin
-800.58%
▼ -1339.8pp YoY
ROIC
-8.29%
▼ -20.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€123K
▼ -93.3% YoY
Op. Cash Flow (TTM)
€2M
▼ -79.2% YoY
Net Debt
€10M
Cash & Equiv.
€1M
3Y CAGR: -18.6%
Continue Research
MPH Health Care (93M1.XETR) trades above a two-stage DCF intrinsic value of about €-1.90 per share, so at €23.60 the stock looks overvalued (108.0% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, MPH Health Care scores 14/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €-1.90 per share for 93M1.XETR, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €-1.42. At today's €23.60, that puts the stock about 108.0% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
MPH Health Care scores 14 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -800.6% operating margin and a -8.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. 93M1.XETR currently trades above its estimated intrinsic value and scores 14/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.